HighTower Advisors LLC Has $1.13 Million Position in Masimo Co. (NASDAQ:MASI)

HighTower Advisors LLC lifted its position in shares of Masimo Co. (NASDAQ:MASI - Free Report) by 41.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 6,813 shares of the medical equipment provider's stock after purchasing an additional 2,003 shares during the period. HighTower Advisors LLC's holdings in Masimo were worth $1,126,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of MASI. Jones Financial Companies Lllp acquired a new position in Masimo during the fourth quarter worth approximately $27,000. UMB Bank n.a. boosted its stake in shares of Masimo by 180.9% during the 4th quarter. UMB Bank n.a. now owns 191 shares of the medical equipment provider's stock worth $32,000 after acquiring an additional 123 shares during the period. Blue Trust Inc. increased its holdings in shares of Masimo by 56.3% during the 4th quarter. Blue Trust Inc. now owns 197 shares of the medical equipment provider's stock worth $33,000 after acquiring an additional 71 shares during the last quarter. Trust Co. of Vermont bought a new stake in Masimo in the 4th quarter valued at $33,000. Finally, Smartleaf Asset Management LLC lifted its holdings in Masimo by 31.6% during the 4th quarter. Smartleaf Asset Management LLC now owns 250 shares of the medical equipment provider's stock valued at $42,000 after purchasing an additional 60 shares during the last quarter. 85.96% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several equities analysts have commented on the stock. Needham & Company LLC reiterated a "hold" rating on shares of Masimo in a report on Wednesday, February 26th. Wells Fargo & Company upped their price target on shares of Masimo from $193.00 to $205.00 and gave the company an "overweight" rating in a research note on Wednesday, February 26th. Piper Sandler raised their price objective on shares of Masimo from $210.00 to $215.00 and gave the stock an "overweight" rating in a research report on Wednesday, February 26th. Finally, Raymond James upped their target price on Masimo from $170.00 to $194.00 and gave the company an "outperform" rating in a research report on Friday, December 27th. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $194.80.

Remove Ads

Insider Buying and Selling

In other Masimo news, COO Bilal Muhsin sold 30,000 shares of the firm's stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $167.49, for a total value of $5,024,700.00. Following the transaction, the chief operating officer now directly owns 24,172 shares of the company's stock, valued at $4,048,568.28. This trade represents a 55.38 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Craig B. Reynolds sold 2,053 shares of the business's stock in a transaction that occurred on Friday, March 14th. The shares were sold at an average price of $166.13, for a total transaction of $341,064.89. Following the completion of the transaction, the director now owns 16,581 shares of the company's stock, valued at $2,754,601.53. The trade was a 11.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 9.70% of the stock is owned by company insiders.

Masimo Stock Performance

Masimo stock traded down $4.92 during midday trading on Friday, hitting $163.55. The company's stock had a trading volume of 594,384 shares, compared to its average volume of 640,467. The company has a debt-to-equity ratio of 0.50, a current ratio of 2.01 and a quick ratio of 1.11. The company has a market cap of $8.82 billion, a price-to-earnings ratio of 112.79 and a beta of 1.04. Masimo Co. has a 1-year low of $101.61 and a 1-year high of $194.88. The company has a 50-day moving average price of $174.79 and a two-hundred day moving average price of $161.39.

Masimo (NASDAQ:MASI - Get Free Report) last issued its quarterly earnings results on Tuesday, February 25th. The medical equipment provider reported $1.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.42 by $0.38. Masimo had a return on equity of 14.98% and a net margin of 3.85%. The business had revenue of $600.70 million during the quarter, compared to analysts' expectations of $593.35 million. As a group, sell-side analysts predict that Masimo Co. will post 4.1 earnings per share for the current year.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.